Gilead Presents 48 Week Results of Hepcludex (bulevirtide) in P-III (MYR301) Trial for the Treatment of Chronic Hepatitis Delta Virus at ILC 2022
Shots:
- The P-III (MYR301) trial evaluating Hepcludex (2/10mg, qd) in 150 patients with chronic HDV. The results showed a positive impact of bulevirtide on PROs & reinforce the clinical utility of sustained treatment
- Patients achieved a greater virological & biochemical response (45% & 48%) vs those who had not received antiviral treatment (2%), combined response rates increased from 24 to 48wk. The safety profile was consistent with prior reports with no AE leading to discontinuation & no SAEs
- The company presented an exploratory analysis of 48wk. data of bulevirtide (2mg) showed improvements from baseline & daily activities. In the control group, patients remained unchanged apart from improvements in health distress & hepatitis-specific health distress
Ref: Bussinesswire | Image: Gilead
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
